Mogamulizumab Q4week Dosing in Participants With R/R CTCL


I'm Interested

Trial ID: NCT04745234


This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Official Title

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Stanford Investigator(s)

Youn H Kim, MD
Youn H Kim, MD

The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)


Inclusion Criteria:

   - Histologically confirmed diagnosis of MF or SS

      - Stage IB, II-A, II-B, III, or IV;

   - Participants who have failed at least one prior course of systemic therapy (e.g.,
   interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus
   ultraviolet light therapy (PUVA) is not considered a systemic therapy.

Exclusion Criteria:

   - Current evidence of large cell transformation;

   - Prior treatment with mogamulizumab;

   - History of allogeneic transplant.


drug: Mogamulizumab


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kumari Khushboo

New Trial Alerts